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Orbital spaceflight perturbs the human immune 
system significantly; Natural Killer (NK) and T-
lymphocyte (T) cell functions are most susceptible 
to spaceflight-induced impairment. This loss of 
function may manifest in persistent latent virus 
reactivation (CMV, EBV, VZV), which does occur 
at a higher frequency in astronauts compared to 
earthlings. 
The definition of a countermeasure strategy to 
immune depression is a prerequisite for deep-
space exploration. To this end, an Earth analog for 
the space exposome would facilitate the process 
greatly. Winter-over (WO) missions on Antarctica 
reproduce profound stressors associated with 
space: extreme temperatures, circadian 
misalignment, and isolation. Here, we update the 
progress of two research projects -- at Concordia 
Station (interior) and Neumayer-III Station 
(coastal) -- that assessed the effect of Antarctica 
WO stay on immunity and latent herpesvirus 
reactivation.
Previously, the ESA-NASA CHOICE I study 
evaluated immune dysregulation during WO at the 
interior Concordia Station. The data revealed 
significant dysregulation persisted in 
crewmembers, but many aspects were dissimilar 
from those defined during spaceflight. The 
differences may be due to the confounding 
influence of hypobaric hypoxia; Concordia sits at 
an elevation of over 14,000 feet. Nonetheless, a 
follow-up study (CHOICE II) study at Concordia 
Station was implemented to define a mechanistic 
understanding of the relationship between stress, 
isolation, and hypobaric hypoxia on immunity.
In parallel, NASA selected an immune 
evaluation to be performed at Neumayer Station --
Choice-Coastal – to determine if the coastal, and 
relatively normoxic, base recapitulates the space 
exposome more precisely than the interior base. 
In association with the Behavioral Hybrid Training 
investigation (M. Basner, PI), this study 
incorporated immune assays from the NASA 
Integrated Immune and ESA Immuno 
investigations aboard ISS. Therefore we will be 
able to compare directly previous data from flight-
to-ground missions with those from Antarctica 
interior and coastal (hypoxic versus normoxic, 
respectively) WO missions.
Our goals are:
1. To define the mechanism of stress-induced 
immune cell impairment.
2. To identify a ground (Antarctica?) space 
analog for immune countermeasure 
development and validation studies. 
METHODOLOGY
Eight subjects were deployed for winter-over 
isolation during the first 11 months or each study 
year, 2016 and 2017 (n =16 total). Blood 
specimens were collected monthly at the base, 
and then processed for plasma and flow 
cytometric analysis. 
An on-location flow cytometer was installed at 
Concordia Station for real-time acquisition. Pre-
and post- mission samples (baseline) were 
collected in Europe. The flow cytometry data was 
sent to the Immunology lab at JSC for analysis in 
2018. A shipment containing all the frozen plasma 
and whole blood specimens from both the WO 
2016 and 2017 seasons was received at JSC in 
November 2018; analyses of these samples will 
be completed in FY2019.
A variety of ESA-led assays to define “omics” 
and epigenetic alterations during prolonged 
confinement in hypobaric hypoxic conditions.   
NASA will contribute a suite of previously 
validated assays that defined immune 
dysregulation in astronauts. 
PROGRAM RELEVANCE
• HHC risk: ‘Risk of adverse crew health event 
due to altered immune response’
• HHC GAP IM-03: ‘Lack of a suitable ground 
analog for spaceflight-associated immune 
dysregulation’, as identified in the SAT report 
and the current HRP IRP rev D.
• The identification of the most appropriate 
ground based space flight analog for 
spaceflight-associated immune dysregulation is 
necessary to enable mechanistic assessments, 
development of a validation strategy, and the 
ground-based validation of immune 
countermeasures. Any likely analog will be 
validated by comparing its ground data to the 
in-flight immune data generated during the 
Integrated and Functional Immune flight studies 
(SMO-015). 
PRELIMINARY RESULTS
• Bulk leukocyte distribution (A protocol), for the 
CHOICE II subjects
SUMMARY CONCLUSION
• Data collection during the 2017 session versus 
the 2016 session was much more consistent. 
While the results from 2016 demonstrate 
profound fluctuations during the winter months, 
those from 2017 indicate a relatively constant 
frequency in all cell types. Without a knowledge 
of particular activities or events that may have 
influenced the data, the gaps in sample 
collection and the overall inferior quality of the 
flow data from the 2016 session suggest the 
discrepancy in the data patterns between the 
two WO sessions is most likely attributable to 
technical error rather than true immune 
perturbations. 
• Data from the remaining samples in repository 
will determine the prospect of a coastal base as 
a site for countermeasure validation.
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